Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2025
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)
5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...
Posted by Michael Wonder on 05 Feb 2025
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)
5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...
Posted by Michael Wonder on 04 Feb 2025
Comanche Biopharma awarded Innovation passport designation by the UK Innovative Licensing and Access Pathway Steering Group for CBP-4888, an investigational siRNA drug candidate for the treatment of sFlt1-mediated preterm pre-eclampsia
30 January 2025 - A novel investigational drug candidate, CBP-4888 leverages the precise targeting ability of siRNAs to downregulate sFlt1 ...
Posted by Michael Wonder on 04 Feb 2025
Durvalumab with tremelimumab for the first-line treatment of patients with advanced or unresectable hepatocellular carcinoma
4 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Feb 2025
The use of real world data for estimating relative treatment effects in NICE health technology assessment submissions: a review
1 February 2025 - This paper investigates the current use of real world data for estimating relative treatment effects in NICE ...
Posted by Michael Wonder on 01 Feb 2025
Groundbreaking one-off gene therapy approved for severe sickle cell disease
31 January 2025 - People in England with severe sickle cell disease will be among the first to receive treatment using ...
Posted by Michael Wonder on 31 Jan 2025
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease in England
31 January 2025 - Agreement means eligible sickle cell disease patients in England now have access to Casgevy. ...
Posted by Michael Wonder on 31 Jan 2025
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
30 January 2025 - We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life. ...
Posted by Michael Wonder on 28 Jan 2025
Spesolimab for the treatment of patients with generalised pustular psoriasis flares
24 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jan 2025
Harnessing expertise to improve patient access to innovative health technologies
28 January 2025 - Introducing the Medicines and Medical Devices Access Initiative: a new collaboration that aims to improve patient access ...
Posted by Michael Wonder on 28 Jan 2025
Tarlatamab for previously treated patients with advanced small-cell lung cancer
28 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 25 Jan 2025
Garadacimab (Andembry) approved to prevent angioedema attacks
24 January 2025 - The MHRA has today approved garadacimab (Andembry) for patients aged 12 years and older with hereditary angioedema ...
Posted by Michael Wonder on 23 Jan 2025
Vadadustat for the treatment of adults with symptomatic anaemia on dialysis for chronic kidney disease
23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...
Posted by Michael Wonder on 22 Jan 2025
Abiraterone acetate with niraparib tosylate monohydrate and prednisone for untreated hormone-relapsed metastatic prostate cancer
22 January 2025 - NICE is unable to make a recommendation on the use in the NHS of abiraterone acetate with ...
Posted by Michael Wonder on 21 Jan 2025
NICE has made six times more lung cancer treatment recommendations over the past ten years than in the previous decade
21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...